- Home
- BYRN vs SLDB Comparison
BYRN vs SLDB Comparison
Compare BYRN & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYRN
- SLDB
- Stock Information
- Founded
- BYRN 2005
- SLDB 2013
- Country
- BYRN United States
- SLDB United States
- Employees
- BYRN N/A
- SLDB N/A
- Industry
- BYRN Industrial Machinery/Components
- SLDB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BYRN Miscellaneous
- SLDB Health Care
- Exchange
- BYRN Nasdaq
- SLDB Nasdaq
- Market Cap
- BYRN 530.6M
- SLDB 464.1M
- IPO Year
- BYRN N/A
- SLDB 2018
- Fundamental
- Price
- BYRN $21.01
- SLDB $5.92
- Analyst Decision
- BYRN Strong Buy
- SLDB Strong Buy
- Analyst Count
- BYRN 2
- SLDB 10
- Target Price
- BYRN $41.50
- SLDB $15.00
- AVG Volume (30 Days)
- BYRN 714.6K
- SLDB 1.0M
- Earning Date
- BYRN 10-09-2025
- SLDB 11-07-2025
- Dividend Yield
- BYRN N/A
- SLDB N/A
- EPS Growth
- BYRN 543.53
- SLDB N/A
- EPS
- BYRN 0.66
- SLDB N/A
- Revenue
- BYRN $110,853,000.00
- SLDB N/A
- Revenue This Year
- BYRN $39.83
- SLDB N/A
- Revenue Next Year
- BYRN $20.47
- SLDB N/A
- P/E Ratio
- BYRN $31.89
- SLDB N/A
- Revenue Growth
- BYRN 50.99
- SLDB N/A
- 52 Week Low
- BYRN $13.68
- SLDB $2.41
- 52 Week High
- BYRN $34.78
- SLDB $7.37
- Technical
- Relative Strength Index (RSI)
- BYRN 45.98
- SLDB 50.88
- Support Level
- BYRN $19.46
- SLDB $5.48
- Resistance Level
- BYRN $25.42
- SLDB $6.09
- Average True Range (ATR)
- BYRN 1.86
- SLDB 0.38
- MACD
- BYRN -0.32
- SLDB -0.03
- Stochastic Oscillator
- BYRN 13.90
- SLDB 40.00
About BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.
About SLDB Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.